Medical Innovation Exchange

After deeming success unlikely, Merck KGaA cuts lung cancer trial to consider future of ATR inhibitor


Leave a Comment

Your email address will not be published.

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.